Opinion
Video
Additional Immunotherapies on the Horizon for LS-SCLC
Author(s):
Panelists discuss how atezolizumab is being investigated in the NRG-LU005 trial for limited-stage small cell lung cancer (SCLC), comparing its trial design with that of the ADRIATIC study, while also exploring the potential benefits of using a single immunotherapy across all SCLC stages and considering treatment strategies for patients who progress from limited-stage to extensive-stage disease while on immunotherapy.
EP: 1.Introduction: Risk Factors and Characteristics Defining SCLC
EP: 2.Established Multidisciplinary Therapies for SCLC
EP: 3.Immunotherapies for Extensive-Stage SCLC
EP: 4.Introducing Bispecifics for Extensive-Stage SCLC
EP: 5.Standard of Care Durvalumab for Limited-Stage SCLC
EP: 6.Additional Immunotherapies on the Horizon for LS-SCLC
Atezolizumab is also being investigated in the NRG-LU005 trial in patients with limited-stage small cell lung cancer (SCLC).
- What potential role could atezolizumab have in patients with limited-stage disease?
- What is the design of this trial?
- How does the trial design differ from the ADRIATIC trial?
Are there synergies or efficiencies in using a single immunotherapy in all stages of SCLC?
If a patient progresses from limited-stage to extensive-stage disease on immunotherapy, do you switch therapies or continue the same regimen?
